---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123727"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:55:04.995596+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sana Biotechnology Q3 2024 net loss $59.9M; advancing three clinical programs; cash runway into 2026

## Summary
- Net loss of $59.9M ($0.25/sh) for Q3 2024 vs net income of $1.0M in Q3 2023.
- Cash and equivalents $199.0M as of Sep 30, 2024; expected cash runway into 2026.
- Appointed Dhaval Patel as Chief Scientific Officer; expanding focus on type 1 diabetes and B-cell autoimmune diseases.
- Enrolling patients in three studies: UP421 (type 1 diabetes), GLEAM (SC291 autoimmune), VIVID (SC262 oncology); data expected in 2024/2025.
- Non-GAAP operating cash burn $153.1M for first nine months 2024; strategic repositioning may increase 2024 burn above prior guidance of <$200M.

## SEC filing metadata
- accession: 0000950170-24-123727
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000095017024123727/0000950170-24-123727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000095017024123727/sana-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123727
- JSON: https://secwatch.observer/filing/0000950170-24-123727.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123727.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.